NDC-1308 DUAL MECHANISM OF ACTION
NDC-1308Dual Mechanism of Action Up-regulates Key Genes Required for Remyelination
ENDECE Approach To Remyelination
ENDECE has discovered and is developing NDC-1308, a new therapy with a dual mechanism of action (MOA) designed to provide the necessary anti-inflammatory, pro-repair environment at lesions and upregulate genes necessary for inducing OPCs to differentiate into mature oligodendrocytes responsible for remyelination.
For more information go to About NDC-1308
NDC-1308 Induces Remyelination at the Gene Transcription Level
NDC-1308 Upregulates Key Genes Required for OPC Differentiation Into Mature Oligodendrocytes.
Upregulating LPL Causes Polarization of Macrophages to M2 State.
To learn more go to:
A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome.
To learn more go to Developing NDC-1308